Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5912-5919

  Mirchandani, Deepu ^b   Hochster, Howard ^a   Hamilton, Anne ^c   Liebes, Leonard ^a   Yee, Herman ^a   Curtin, John P ^a   Lee, Sang ^a   Sorich, Joan ^a   Dellenbaugh, Cornelia ^a   Muggia, Franco M ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; IRINOTECAN; LACTONE; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TOXICITY TESTING; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TOPOTECAN; TREATMENT OUTCOME; VOMITING;

EID: 23844469797     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1240     Document Type: Article

References (45)

1. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics and tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
2. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-47.
3. O'Brien ME, Wigler N, Inbar M, et al.; CAELYX Breast Cancer study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HC1 (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-9.
4. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
5. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18:3093-100.
6. Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 2001;91:90-100.
7. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36.
8. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
9. Smith PJ, Soues S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br J Cancer 1994;23: S47-51.
10. Nitiss JL, Rose A, Sykes KC, Harris J, Zhou J. Using yeast to understand drugs that target topoisomerases. Ann NY Acad Sci 1996;803:32-43.
11. Licitra EJ, Vyas V, Nelson K, et al. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 2003;9:1673-9.
12. Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994;6:269-79.
13. Takimoto CH, Arbuck SG. The camptothecins in cancer chemotherapy and biotherapy. In: Chabner BA, Longo DL, editors. Philadelphia: Lippincott-Raven, p. 463-84.
14. Potmesil M, Giovanella BC, Liu LF, et al. Preclinical studies of DNA topoisomerase 1-targeted 9-amino and 10,11-methylenedioxy camptothecins. In: Potmesil M, Kohn KW, editors. DNA topoisomerases in cancer. New York: Oxford University Press; 1991. p. 299-311.
15. Hsiang YH, Liu LF. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1998;49:5077-82.
16. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
17. Hochster H. Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-9.
18. Hochster H, Wadler S, Runowicz C, et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999;17:2553-61.
19. Lilenbaum RC, Miller AA, Batist G, et al. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B study J Clin Oncol 1998;16:3302-9.
20. Gerritis C, Schellens J, Burris H, et al. Prolonged exposure to oral topotecan (TPT), correlates between pharmacokinetics and toxicity [abstract 788]. Proc Am Soc Clin Oncol 1997;16:224a.
21. Creemers GJ, Gerrits CJ, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997;15:1087-93.
22. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38:57-63.
23. Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 1994;6:269-79.
24. Eder JP, Chan V, Wong J, et al. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 1998;42:327-35.
25. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase topo I and II [abstract 2573]. Proc Am Assoc Cancer Res 1992;11:431.
26. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
27. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer, results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
28. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-7.
29. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
30. Tolcher AW, O'Shaughnessy JA, Weiss RB, et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 1997;3:755-60.
31. Seiden MV, Ng SW, Supko JG, et al. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res 2002;8:691-7.
32. Pautier P, Germann N, Faivre S, et al. Phase I study of Caelyx (KLX-stealth stabilized liposomal doxorubicin-Doxil) in combination with topotecan [abstract 910], Proc Am Soc Clin Oncol 2000;19:232a.
33. Parimoo D, Garcia AA, Roman L, et al. Phase I trial of liposomal doxorubicin- Doxil (D) and topotecan (T) in advanced pelvic malignancies [abstract 1616]. Proc Am Soc Clin Oncol 2000;19:408a.
34. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A Phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol 2000;23:297-300.
35. Speyer J, Hochster H, Wadler S, et al. Effective first line therapy of ovarian cancer (OC) with cisplatin and prolonged topotecan infusion, a NYGOG/ECOG study [abstract 1503]. Proc Am Soc Clin Oncol 2000;19:380a.
36. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer; a critical need for precise definitions of the treated population. J Clin Oncol 1992;10:513-4.
37. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies, J Clin Oncol 1995;13:1777-85.
38. Oken MM, Creech RH, Jormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
39. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-33.
40. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000;60:831-7.
41. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
42. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6.
43. Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-50.
44. Muggia FM. Boosting bioavailability to topotecan: what do we gain? J Clin Oncol 2003;21:177-8.
45. Muggia FM, Kim E, Gaiotti D. Does maintenance alter the course of recurrent ovarian and endometrial cancer? Experience with pegylated liposomal doxorubicin. Cancer Invest 2004;22:38.